Extended Data Fig. 1: EAG2 and Kvβ2 expression in xenograft GBM tumors, EAG2 localization in GBM cells, EAG2 and Kvβ2 knockdown validation, and tumor growth comparison between control tumor and tumor with knockdown of EAG2, Kvβ2, or both. | Nature Cancer

Extended Data Fig. 1: EAG2 and Kvβ2 expression in xenograft GBM tumors, EAG2 localization in GBM cells, EAG2 and Kvβ2 knockdown validation, and tumor growth comparison between control tumor and tumor with knockdown of EAG2, Kvβ2, or both.

From: A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma

Extended Data Fig. 1

a. EAG2, Kvβ2, GFP, and DAPI expression in G411 xenograft tumor. EAG2, Tau, and GFAP expression in G489, G523, and G532 xenograft tumors. b. Representative images and quantification of EAG2 localization in GBM cells with or without contact of astrocytes. n = 24 cells examined over 3 independent experiments. P values, two-sided unpaired t-test. Error bars, mean ± s.e.m. c. Validation of Dox-induced knockdown of EAG2 and Kvβ2. d. Bioluminescence images show tumor burdens of mice bearing G411 tumors before and after Dox treatment. Kaplan-Meier survival curves are shown. P values, log-rank test. All experiments were performed 3 times using biologically independent samples.

Source data

Back to article page